ReviewChest2012
The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases.
Review in Chest, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Krebs von den Lungen-6 (KL-6) as a diagnostic and prognostic biomarker for non-neoplastic lung diseases.Clinical chemistry and laboratory medicine · 2025Article
- Effects of tetrandrine combined with acetylcysteine on exercise tolerance, pulmonary function and serum TNF-β1 and MMP-7 in silicosis patients.Experimental and therapeutic medicine · 2020Article
- Article
- Causes of Pulmonary Fibrosis in the Elderly.Medical sciences (Basel, Switzerland) · 2018Review
- Secretion of the endoplasmic reticulum stress protein, GRP78, into the BALF is increased in cigarette smokers.Respiratory research · 2017Article
- Article
- Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization.International journal of chronic obstructive pulmonary disease · 2017Article
- Galectin-3 Is Associated with Restrictive Lung Disease and Interstitial Lung Abnormalities.American journal of respiratory and critical care medicine · 2016Article
- Review
- Detection of Rheumatoid Arthritis-Interstitial Lung Disease Is Enhanced by Serum Biomarkers.American journal of respiratory and critical care medicine · 2015Observational
- The Ratio of Free to Bound Desmosine and Isodesmosine May Reflect Emphysematous Changes in COPD.Lung · 2015Article
- Biomarkers of rheumatoid arthritis-associated interstitial lung disease.Arthritis & rheumatology (Hoboken, N.J.) · 2015Article
- Interstitial lung disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.Annals of the American Thoracic Society · 2014Review
- Utility of the CAT in the therapy assessment of COPD exacerbations in China.BMC pulmonary medicine · 2014Article
- Review
- Small Airways Disease, Biomarkers and COPD: Where are We?International journal of chronic obstructive pulmonary diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Recent advances in the field of clinical biomarkers suggest that quantification of serum proteins could play an important role in the diagnosis, classification, prognosis, and treatment response of smoking-related parenchymal lung diseases. COPD and idiopathic pulmonary fibrosis (IPF), two common chronic progressive parenchymal lung diseases, share cigarette smoke exposure as a common dominant risk factor for their development. We have recently shown that COPD and interstitial lung disease may represent distinct outcomes of chronic tobacco use, whereas others have demonstrated that both diseases coexist in some individuals. In this perspective, we examine the potential role of peripheral blood biomarkers in predicting which individuals will develop COPD or IPF, as well as their usefulness in tracking disease progression and exacerbations. Additionally, given the current lack of sensitive and effective metrics to determine an individual's response to treatment, we evaluate the potential role of biomarkers as surrogate markers of clinical outcomes. Finally, we examine the possibility that changes in levels of select protein biomarkers can provide mechanistic insight into the common origins and unique individual susceptibilities that lead to the development of smoking-related parenchymal lung diseases. This discussion is framed by a consideration of the properties of ideal biomarkers for different clinical and research purposes and the best uses for those biomarkers that have already been proposed and investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.